Liver Cirrhosis Market Definition
The liver cirrhosis means the condition that causes scar tissue of the liver to replace healthy liver tissue cells, it happens over the period due to the chronic infection or alcohol addiction. It is diagnosed by various radiology tests such as computed tomography (CT), ultrasound, magnetic resonance imaging (MRI), needle biopsy of the liver. A new imaging technique called elastography, which can be performed with ultrasound or MRI, can also diagnosis cirrhosis.
The market study is broken down by Type (Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis, Cardiac Cirrhosis and Cryptogenic Cirrhosis), by Application (Hospitals, Specialty Clinics and Others) and major geographies with country level splits.
F. Hoffmann-La Roche AG (Switzerland), Merck & Co., Inc (United States), Abbott Laboratories (United States), Novartis International AG (Switzerland), Bristol Myers Squibb Company (United States), Gilead Sciences, Inc (United States), Conatus Pharmaceuticals (United States), GlaxoSmithKline plc (United Kingdom), Grifols, S.A. (Spain), GWOXI Stem Cell Applied Technology Co., Ltd (China), Hepion Pharmaceuticals (United States), Intercept Pharmaceuticals, Inc. (United States) and Lepu Medical Technology (Beijing) Co., Ltd. (China) are some of the key players that are part of study coverage.
AdvanceMarketAnalytics has segmented the market of Global Liver Cirrhosis market by Type, Application and Region.
On the basis of geography, the market of Liver Cirrhosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Self-care will boost the Liver Cirrhosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Stages, the sub-segment i.e. Stage 1 will boost the Liver Cirrhosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Tests, the sub-segment i.e. Computed Tomography (CT) will boost the Liver Cirrhosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Leaders and their expansionary development strategies
On 24th October 2019, Novartis announced the collaboration and license agreement with Pliant Therapeutics to develop and commercialize a preclinical asset, PLN-1474, designed to inhibit the integrin. The agreement also covers a global exclusive license for up to three additional integrin targets. PLN-1474 treats nonalcoholic steatohepatitis (NASH)-related liver fibrosis, which could cause complications, including cirrhosis and liver failure. PLN-1474 demonstrated a significant reduction of fibrosis in live models of human tissue.
On 20th November 2019, Hepion Pharmaceuticals, Inc. announced that CRV431, an anti-fibrotic agent, prevented the development of liver cirrhosis in a highly aggressive, preclinical model of liver disease. In this study, conducted by Physiogenex, S.A.S. (France), rats were administered the hepatotoxic compound, thioacetamide, for nine weeks to induce liver injury and fibrosis, in combination with either CRV431 or vehicle control for the entire study period. Blinded, histopathological analysis of the livers was conducted at the end of the study period.
- Rising Non-alcoholic Fatty Liver Disease
- High Risk of Liver Cirrhosis in Young Adults and Women
- Growing Prevalence of Obesity and Diabetes Problems in People Across the World
- Number of Cases with Viral Infections Like Hepatitis B, C, D, and Alcoholism
- Continuous Research and Development in Liver Cirrhosis Drugs
- Advancements in Liver Cirrhosis Treatment Imaging Devices
- Lengthy Process Involved in Drug and Treatment Research
- Complications Involved with Liver Cirrhosis Treatment
- Expensive Liver Transplantation
Key Target AudienceLiver Cirrhosis Equipment Manufacturer, Liver Cirrhosis Treatment Providers, Research and Development Institutes, Potential Investors, Hospitals, Regulatory Bodies and Others
About ApproachThe research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase